News Releases

Month Year

Su	Mo	Tu	We	Th	Fr	Sa
25	26	27	28	29	30	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Cancel Go

Month Year

Su	Mo	Tu	We	Th	Fr	Sa
25	26	27	28	29	30	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Cancel Go

Email Alerts

Year All Years 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 Keywords Go

Advanced Search

Keywords

  Search Headlines Only

From

To

Asset Types

 Photos  Video  Audio  Documents  Events  Standard

 Basic Search

• Nov 5, 2021

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• Nov 3, 2021

  Insmed To Participate in Three November Conferences
• Oct 28, 2021

  Insmed Ranks No. 1 on Science's 2021 Top Biopharma Employers List
• Oct 28, 2021

  Insmed Reports Third Quarter 2021 Financial Results and Provides Business Update

  --ARIKAYCE® (amikacin liposome inhalation suspension) Now Launched in Three Major Territories; Positive Early Trends in Japan--
• Oct 14, 2021

  Insmed to Host Third Quarter 2021 Financial Results Conference Call on Thursday, October 28, 2021
• Oct 5, 2021

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• Sep 3, 2021

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• Sep 1, 2021

  Insmed To Participate in Five September Conferences
• Aug 6, 2021

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• Aug 5, 2021

  Insmed Reports Second Quarter 2021 Financial Results and Provides Business Update

  --ARIKAYCE® (amikacin liposome inhalation suspension) Now Launched in Japan; Available in Three Major Territories--

Show 5102550100 per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

Sign Up

View the latest Insmed Investor Presentation

Download